Literature DB >> 19207156

Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls.

Manuel Montero-Odasso, Jennie Wells, Michael Borrie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19207156      PMCID： PMC5017867          DOI： 10.1111/j.1532-5415.2009.02085.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  10 in total

1.  Galantamine improves gait performance in patients with Alzheimer's disease.

Authors:  Frédéric Assal; Gilles Allali; Reto W Kressig; François R Herrmann; Olivier Beauchet
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

2.  Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

Authors:  Ben Seltzer; Parvaneh Zolnouni; Margarita Nunez; Robert Goldman; Dinesh Kumar; John Ieni; Sharon Richardson
Journal:  Arch Neurol       Date:  2004-12

3.  Risk factors for falls among elderly persons living in the community.

Authors:  M E Tinetti; M Speechley; S F Ginter
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

4.  Senile dementia of the Alzheimer's type: an important risk factor for serious falls.

Authors:  J C Morris; E H Rubin; E J Morris; S A Mandel
Journal:  J Gerontol       Date:  1987-07

5.  Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years and older.

Authors:  Manuel Montero-Odasso; Marcelo Schapira; Enrique R Soriano; Miguel Varela; Roberto Kaplan; Luis A Camera; L Marcelo Mayorga
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-10       Impact factor: 6.053

Review 6.  Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses.

Authors:  David Oliver; James B Connelly; Christina R Victor; Fiona E Shaw; Anne Whitehead; Yasemin Genc; Alessandra Vanoli; Finbarr C Martin; Margot A Gosney
Journal:  BMJ       Date:  2006-12-08

7.  Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer's disease.

Authors:  Pamela L Sheridan; Judi Solomont; Neil Kowall; Jeffrey M Hausdorff
Journal:  J Am Geriatr Soc       Date:  2003-11       Impact factor: 5.562

Review 8.  Prevention of falls in older people with dementia.

Authors:  F E Shaw
Journal:  J Neural Transm (Vienna)       Date:  2007-06-08       Impact factor: 3.575

Review 9.  The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer's disease.

Authors:  Pamela L Sheridan; Jeffrey M Hausdorff
Journal:  Dement Geriatr Cogn Disord       Date:  2007-07-04       Impact factor: 2.959

10.  Gait variability: methods, modeling and meaning.

Authors:  Jeffrey M Hausdorff
Journal:  J Neuroeng Rehabil       Date:  2005-07-20       Impact factor: 4.262
  10 in total
  14 in total

Review 1.  The interplay between gait, falls and cognition: can cognitive therapy reduce fall risk?

Authors:  Orit Segev-Jacubovski; Talia Herman; Galit Yogev-Seligmann; Anat Mirelman; Nir Giladi; Jeffrey M Hausdorff
Journal:  Expert Rev Neurother       Date:  2011-07       Impact factor: 4.618

2.  Executive control deficits as a prodrome to falls in healthy older adults: a prospective study linking thinking, walking, and falling.

Authors:  Talia Herman; Anat Mirelman; Nir Giladi; Avraham Schweiger; Jeffrey M Hausdorff
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-19       Impact factor: 6.053

3.  Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease.

Authors:  Olivier Beauchet; Cyrille P Launay; Gilles Allali; François R Herrmann; Cedric Annweiler
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

4.  Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Noam U Epstein; Rong Guo; Martin R Farlow; Jaswinder P Singh; Morris Fisher
Journal:  Drugs Aging       Date:  2014-02       Impact factor: 3.923

5.  Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.

Authors:  O Beauchet; C P Launay; G Allali; C Annweiler
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

6.  Advances in Therapeutic Options for Gait and Balance in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Roger L Albin; Martijn L T M Müller; Kelvin Chou
Journal:  US Neurol       Date:  2011-11-01

Review 7.  Gait and cognition: a complementary approach to understanding brain function and the risk of falling.

Authors:  Manuel Montero-Odasso; Joe Verghese; Olivier Beauchet; Jeffrey M Hausdorff
Journal:  J Am Geriatr Soc       Date:  2012-10-30       Impact factor: 5.562

8.  Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.

Authors:  Dae Hyun Kim; Rebecca T Brown; Eric L Ding; Douglas P Kiel; Sarah D Berry
Journal:  J Am Geriatr Soc       Date:  2011-06-07       Impact factor: 5.562

9.  Adaptive walking in Alzheimer's disease.

Authors:  Diego Orcioli-Silva; Lucas Simieli; Fabio Augusto Barbieri; Florindo Stella; Lilian Teresa Bucken Gobbi
Journal:  Int J Alzheimers Dis       Date:  2012-09-09

10.  Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial.

Authors:  Manuel Montero-Odasso; Jennie L Wells; Michael J Borrie; Mark Speechley
Journal:  BMC Neurol       Date:  2009-08-12       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.